Literature DB >> 3318619

The membrane attack complex of complement at the endplate in myasthenia gravis.

A G Engel1, K Arahata.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1987        PMID： 3318619     DOI： 10.1111/j.1749-6632.1987.tb51301.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN： 0077-8923            Impact factor:   5.691


× No keyword cloud information.
  26 in total

Review 1.  Current Treatment, Emerging Translational Therapies, and New Therapeutic Targets for Autoimmune Myasthenia Gravis.

Authors:  Jeffrey T Guptill; Madhu Soni; Matthew N Meriggioli
Journal:  Neurotherapeutics       Date:  2016-01       Impact factor: 7.620

2.  Antibodies against low-density lipoprotein receptor-related protein 4 induce myasthenia gravis.

Authors:  Chengyong Shen; Yisheng Lu; Bin Zhang; Dwight Figueiredo; Jonathan Bean; Jiung Jung; Haitao Wu; Arnab Barik; Dong-Min Yin; Wen-Cheng Xiong; Lin Mei
Journal:  J Clin Invest       Date:  2013-11-08       Impact factor: 14.808

Review 3.  Complement membrane attack on nucleated cells: resistance, recovery and non-lethal effects.

Authors:  B P Morgan
Journal:  Biochem J       Date:  1989-11-15       Impact factor: 3.857

Review 4.  Mechanisms of Autoantibody-Induced Pathology.

Authors:  Ralf J Ludwig; Karen Vanhoorelbeke; Frank Leypoldt; Ziya Kaya; Katja Bieber; Sandra M McLachlan; Lars Komorowski; Jie Luo; Otavio Cabral-Marques; Christoph M Hammers; Jon M Lindstrom; Peter Lamprecht; Andrea Fischer; Gabriela Riemekasten; Claudia Tersteeg; Peter Sondermann; Basil Rapoport; Klaus-Peter Wandinger; Christian Probst; Asmaa El Beidaq; Enno Schmidt; Alan Verkman; Rudolf A Manz; Falk Nimmerjahn
Journal:  Front Immunol       Date:  2017-05-31       Impact factor: 7.561

Review 5.  Complementopathies and precision medicine.

Authors:  Eleni Gavriilaki; Robert A Brodsky
Journal:  J Clin Invest       Date:  2020-05-01       Impact factor: 14.808

Review 6.  Role of complement and potential of complement inhibitors in myasthenia gravis and neuromyelitis optica spectrum disorders: a brief review.

Authors:  Jayne L Chamberlain; Saif Huda; Daniel H Whittam; Marcelo Matiello; B Paul Morgan; Anu Jacob
Journal:  J Neurol       Date:  2019-09-03       Impact factor: 4.849

Review 7.  Membrane signaling by complement C5b-9, the membrane attack complex.

Authors:  A Nicholson-Weller; J A Halperin
Journal:  Immunol Res       Date:  1993       Impact factor: 2.829

8.  MuSK IgG4 autoantibodies cause myasthenia gravis by inhibiting binding between MuSK and Lrp4.

Authors:  Maartje G Huijbers; Wei Zhang; Rinse Klooster; Erik H Niks; Matthew B Friese; Kirsten R Straasheijm; Peter E Thijssen; Hans Vrolijk; Jaap J Plomp; Pauline Vogels; Mario Losen; Silvère M Van der Maarel; Steven J Burden; Jan J Verschuuren
Journal:  Proc Natl Acad Sci U S A       Date:  2013-12-02       Impact factor: 11.205

9.  Novel complement inhibitor limits severity of experimentally myasthenia gravis.

Authors:  Jindrich Soltys; Linda L Kusner; Andrew Young; Chelliah Richmonds; Denise Hatala; Bendi Gong; Vaithesh Shanmugavel; Henry J Kaminski
Journal:  Ann Neurol       Date:  2009-01       Impact factor: 10.422

Review 10.  Autoimmune synaptopathies.

Authors:  Sarah J Crisp; Dimitri M Kullmann; Angela Vincent
Journal:  Nat Rev Neurosci       Date:  2016-02       Impact factor: 34.870
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.